CytoCore Announces Year End Results.

CHICAGO -- CytoCore (OTCBB:CYCR), the late-stage bio-scientific research and medical device company for early detection and treatment of reproductive-tract cancers, reports a loss of $ .03 per share for 2006 compared to a loss per share of $.04 per share for 2005. Net sales were $94,000 in 2006 compared to $117,000 in 2005. Cash balances at the end of 2006 were $874,000 vs. zero for 2005.

According to CytoCore CFO Robert McCullough Jr., 2006 represented a major transition year as the company resumed clinical trials on two products (the e2 Collector and the EndoScan test) and has completed the reduction of a substantial amount of its debt. Also during 2006, CytoCore resumed product development for the family of products which comprise the InPath System[TM]. This includes further research and development on the new P2X7 genetic biomarker (currently in clinical trials), which is the lead protein antibody assay in the InPath System.

Early research indicates that the P2X7 biomarker has the potential for detection and highlighting of abnormal cancerous cells. This could lead to possible application for the detection of endometrial and uterine cancers. CytoCore has also initiated a marketing confirmation trial of the FDA-approved e2 Collector and resumed product development for the Automated Image Proteomic System (AIPS) workstation. All of these products will eventually be incorporated into the InPath System which is intended to provide a "point of care" screening system. As stated in earlier press releases CytoCore is anticipating the sales launch of the e2 Collector later in 2007 and is currently ramping up volume production capabilities.

CytoCore has reduced debt from $13.4 million at June 30, 2005 to $4.1 million at December 31, 2006. Approximately, 32% of liabilities as of December 31, 2006 represent reserves for non-recurring expenses.

According to McCullough, "By mid-year 2007, we are expecting that the December 31, 2006 debt balance will reflect primarily current trade payables only. CytoCore has raised approximately $4 million in equity during the first quarter 2007. We will be issuing guidance next week on the first Quarter's activities. We are excited that going forward CytoCore resources will be focused on product development, manufacturing and sales."

About CytoCore Inc.

CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath[TM] System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com

Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath[TM] System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2006. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.